Legal Representation
Attorney
ANDREW D. PRICE
USPTO Deadlines
Next Deadline
1532 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2023-09-19)
Due Date
September 19, 2029
Grace Period Ends
March 19, 2030
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
39 events| Date | Code | Type | Description |
|---|---|---|---|
| Nov 20, 2024 | ASCK | I | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY |
| Sep 19, 2023 | R.PR | A | REGISTERED-PRINCIPAL REGISTER |
| Sep 19, 2023 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
| Aug 10, 2023 | DP1B | I | 1(B) BASIS DELETED; PROCEED TO REGISTRATION |
| Aug 10, 2023 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| Jun 20, 2023 | D1BR | I | TEAS DELETE 1(B) BASIS RECEIVED |
| Jun 20, 2023 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Jun 20, 2023 | IUCN | S | NOTICE OF ALLOWANCE CANCELLED |
| Apr 25, 2023 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Apr 25, 2023 | PUBO | A | PUBLISHED FOR OPPOSITION |
| Apr 5, 2023 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Mar 22, 2023 | FIXD | O | ELECTRONIC RECORD REVIEW COMPLETE |
| Mar 20, 2023 | EXPT | T | EXPARTE APPEAL TERMINATED |
| Mar 17, 2023 | ERRR | O | ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED |
| Mar 16, 2023 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Dec 28, 2022 | ASCK | I | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY |
| Sep 16, 2022 | GNS3 | O | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED |
| Sep 16, 2022 | GNSL | S | LETTER OF SUSPENSION E-MAILED |
| Sep 16, 2022 | CNSL | R | SUSPENSION LETTER WRITTEN |
| Sep 8, 2022 | ERFR | I | TEAS REQUEST FOR RECONSIDERATION RECEIVED |
| Sep 8, 2022 | EXPI | T | EX PARTE APPEAL-INSTITUTED |
| Sep 8, 2022 | JURT | T | JURISDICTION RESTORED TO EXAMINING ATTORNEY |
| Sep 8, 2022 | EXAF | T | EXPARTE APPEAL RECEIVED AT TTAB |
| Mar 8, 2022 | GNFN | O | NOTIFICATION OF FINAL REFUSAL EMAILED |
| Mar 8, 2022 | GNFR | O | FINAL REFUSAL E-MAILED |
| Mar 8, 2022 | CNFR | R | FINAL REFUSAL WRITTEN |
| Mar 7, 2022 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Mar 7, 2022 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Mar 7, 2022 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Oct 6, 2021 | GEAN | O | NOTIFICATION OF EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED |
| Oct 6, 2021 | GEAP | F | EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED |
| Oct 6, 2021 | EPEN | O | COMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION AUTOMATIC ENTRY |
| Oct 6, 2021 | CPEA | R | EXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED |
| Oct 4, 2021 | DOCK | D | ASSIGNED TO EXAMINER |
| Jun 24, 2021 | AMPX | O | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED |
| Jun 17, 2021 | ALIE | A | ASSIGNED TO LIE |
| Jun 10, 2021 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Mar 29, 2021 | PARI | I | TEAS VOLUNTARY AMENDMENT RECEIVED |
| Mar 13, 2021 | NWAP | I | NEW APPLICATION ENTERED |
Detailed Classifications
Class 005
Pharmaceutical preparations for the treatment of cancer, viral infections, and tumorous diseases; biological preparations for the treatment of viral infections; biological preparations for medical use for the treatment of tumorous diseases; immunotherapeutic drugs, namely, pharmaceutical preparations for the treatment of cancer, viral infections, tumorous diseases; reagents for medical use; diagnostic preparations for medical purposes; diagnostic reagents for medical use; medical diagnostic reagents used in connection with drug discovery, namely, the identification of pharmaceutical targets and the development of molecules to be used for medicinal or therapeutic purposes; medical diagnostic reagents used in connection with protein engineering and biological drug development; all of the foregoing excluding treatment of osteoarticular disorders, of bone and joint pathologies, of musculoskeletal pathologies and of degenerative and chronic inflammatory pathologies, vertebral-spinal pathologies and disorders, degenerative and chronic inflammatory pathologies, inflammatory pathologies due to rheumatic disorders, or trauma or auto-immune conditions
Class 042
Scientific and technological services, namely, pharmaceutical research and design relating thereto; pharmaceutical research and development services; pharmaceutical testing and clinical trials; research and development in the biotechnology field; drug discovery, namely, the identification of pharmaceutical targets and the development of molecules to be used for medicinal or therapeutic purposes; protein engineering and biological drug development; provision of information and consultancy in relation to the aforesaid services; all of the foregoing excluding treatment of osteoarticular disorders, of bone and joint pathologies, of musculoskeletal pathologies and of degenerative and chronic inflammatory pathologies, vertebral-spinal pathologies and disorders, degenerative and chronic inflammatory pathologies, inflammatory pathologies due to rheumatic disorders, or trauma or auto-immune conditions
Classification
International Classes
005
042